India, May 19 -- French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April 2041.
In Paris, AB Science shares were gaining around 7.5 percent to trade at 1.5740 euros.
The Chinese Patent Office has issued a patent providing intellectual property protection for its lead compound masitinib to methods of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing COVID-19, i.e. a medical use patent. The new Chinese patent adds one more indication with long term intellectual property protection, the firm noted.
AB Science said it signed an exclusive licensing agreement, as part of a collaborative research...